معرفی
Thomas A. Bayer is a Professor of Molecular Psychiatry at the University Medical Center Göttingen, University of Göttingen, where he has served since 2007. His research is centered on the molecular mechanisms underlying Alzheimer's disease, with a focus on amyloid-β pathology, transgenic mouse models, and preclinical therapeutic strategies. He leads an active research group and is affiliated with several interdisciplinary neuroscience graduate programs, including GGNB’s Neurosciences and Molecular Medicine tracks.
His research interests include the pathogenesis of Alzheimer's disease, neuronal cell death, development and characterization of mouse models (Tg4-42), preclinical therapy studies, and immunization strategies targeting Aβ. His work integrates neuropathology, biochemistry, behavioral testing, and molecular biology to understand disease mechanisms and identify novel therapeutic targets.
His recent publications highlight a strong focus on N-truncated and pyroglutamate-modified forms of Aβ, their structural properties, and their role in neurodegeneration. Trends in his research show a consistent emphasis on identifying druggable targets within the Aβ cascade, improving vaccine design, and validating therapeutic antibodies using transgenic models and post-mortem human tissue.
He has received funding from major bodies such as the European Commission, having coordinated the International Alzheimer PhD School on neurodegeneration. While specific awards are not listed, his leadership in large collaborative programs underscores recognition in the field.
Professor Bayer advises graduate students through the GGNB programs and is involved in training the next generation of neuroscientists. His lab continues to explore innovative approaches to Alzheimer’s therapy, including structural vaccinology and targeted immunomodulation.
